1 / 30

Toward a multi-modality approach to radiotherapy for cancer treatment in UK (Unity is strength)

Toward a multi-modality approach to radiotherapy for cancer treatment in UK (Unity is strength). Barbara Camanzi STFC – RAL & University of Oxford. Outline. Why cancer Radiotherapy Toward multi-modality The technological challenges: dosimetry and imaging Conclusions.

tiana
Download Presentation

Toward a multi-modality approach to radiotherapy for cancer treatment in UK (Unity is strength)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Toward a multi-modality approach to radiotherapyfor cancer treatment in UK(Unity is strength) Barbara Camanzi STFC – RAL & University of Oxford

  2. Outline • Why cancer • Radiotherapy • Toward multi-modality • The technological challenges: dosimetry and imaging • Conclusions NPAE-Kyiv2010, Kiev, 7-12/06/10

  3. The challenge of cancer in UK • Cancer is the leading cause of mortality in people under the age of 75. 1 in 4 people die of cancer overall • 293k people/year diagnosed with cancer, 155k people/year die from cancer • Incidence of cancer is rising due to: • Population ageing • Rise in obesity levels • Change in lifestyle • Cancer 3rd largest NHS disease programme NPAE-Kyiv2010, Kiev, 7-12/06/10

  4. Radiotherapy NPAE-Kyiv2010, Kiev, 7-12/06/10

  5. Radiotherapy and cancer in UK • Radiotherapygiven to 1/3 of cancer patients (10-15% of all population) • Overall cure rate = 40%. In some instances 90-95% (for ex. breast and stage 1 larynx cancers) • Radiotherapy often combined with other cancer treatments: • Surgery • Chemotherapy • Hormone treatments NPAE-Kyiv2010, Kiev, 7-12/06/10

  6. Radiotherapy treatments • External beam radiotherapy: • X-ray beam • Electron beam • Proton/light ion beam • Internal radiotherapy: • Sealed sources (brachytherapy) • Radiopharmaceuticals • Binary radiotherapy: • Boron Neutron Capture Therapy (BNCT) • Photon Capture Therapy (PCT) NPAE-Kyiv2010, Kiev, 7-12/06/10

  7. A new approach to radiotherapy • Cure cancer & protect healthy tissues • Dose escalation in tumour • Minimise dose to normal tissues • Different treatment strategies are required depending on cancer type, stage and degree of spread • Radiotherapy treatments not linked = impact lowered = missed opportunity → New approach needed NPAE-Kyiv2010, Kiev, 7-12/06/10

  8. My vision: multi-modality • Unified approach to radiotherapy needed to maximise efficacyand improve care • Multi-modality = bringing together the different forms of radiotherapy treatments: • Select best treatment depending on tumour type • Combine different treatments when appropriate • Highly beneficial to patient: better local control and lower toxicity NPAE-Kyiv2010, Kiev, 7-12/06/10

  9. Multi-modality: selection • External beam and internal radiotherapy best for localised diseases • Binary therapy best for locally spread diseases with high degree of infiltration • Proton/light ion therapy very promising for paediatric tumours • Some other considerations: • Proximity of organs at risk • Tumour dimension and location • Previous irradiation (recurrences) NPAE-Kyiv2010, Kiev, 7-12/06/10

  10. Multi-modality: combination • Combination of different sources → dose escalation • Different organs at risk for various treatments → toxicity not increased • Some examples: • External beam therapy + brachytherapy • External beam therapy + radiopharmaceuticals NPAE-Kyiv2010, Kiev, 7-12/06/10

  11. The challenge NPAE-Kyiv2010, Kiev, 7-12/06/10

  12. The technological challenges • The challenge of radiotherapy from the patient end Make sure that the right dose is delivered at the right place = improved dosimetry + improved imaging • The challenge of early diagnosis “See” smaller tumours = improved imaging • New advanced technologies desperately needed for dosimetry and imaging NPAE-Kyiv2010, Kiev, 7-12/06/10

  13. How particle physics can help "The significant advances achieved during the last decades in material properties, detector characteristics and high-quality electronic system played an ever-expanding role in different areas of science, such as high energy, nuclear physics and astrophysics. And had a reflective impact on the development and rapid progress of radiation detector technologies used in medical imaging." “The requirements imposed by basic research in particle physics are pushing the limits of detector performance in many regards, the new challenging concepts born out in detector physics are outstanding and the technological advances driven by microelectronics and Moore's law promise an even more complex and sophisticated future.” D. G. Darambara "State-of-the-art radiation detectors for medical imaging: demands and trends" Nucl. Inst. And Meth. A 569 (2006) 153-158 NPAE-Kyiv2010, Kiev, 7-12/06/10

  14. State-of-the-Art NPAE-Kyiv2010, Kiev, 7-12/06/10

  15. Dosimetry • All external dosimeters placed on patient skin: • TLDs • Diodes • MOSFETs • Disadvantages: • No reading at tumour site • No real-time information for some (TLDs) • Difficult to use (wires: diodes, MOSFETs) NPAE-Kyiv2010, Kiev, 7-12/06/10

  16. Gamma camera (SPECT) CT scanner Scintillator Diode Collimator Courtesy Mike Partridge (RMH/ICR) Imaging • Most medical imaging systems, CT, gamma cameras, SPECT, PET, use particle physics technologies: scintillating materials, photon detectors, CCDs, etc. NPAE-Kyiv2010, Kiev, 7-12/06/10

  17. 511 keV g 511 keV g Courtesy Mike Partridge (RMH/ICR) Positron Emission Tomography • 18F labelled glucose given to patients: e+ annihilates in two back-to-back 511 keV g • A ring of scintillating crystals and PMTs detects the g NPAE-Kyiv2010, Kiev, 7-12/06/10

  18. Courtesy Mike Partridge (RMH/ICR) PET CT PET + CT Conventional PET Conventional PET scanner: • Coincidences formed within a very short time window • Straight line-of-response reconstructed • Position of annihilation calculated probabilistically NPAE-Kyiv2010, Kiev, 7-12/06/10

  19. The future NPAE-Kyiv2010, Kiev, 7-12/06/10

  20. The dosimetry challenge • The requirements for new dosimeters: • Measure dose at tumour site and not at skin • Measure total dose (including during imaging procedures) • Measure in real-time and not long time after each treatment fraction • System easy to use • The answer: in-vivo dosimetry NPAE-Kyiv2010, Kiev, 7-12/06/10

  21. In-vivo dosimetry • Radiation sensitive MOSFET transistors (RadFETs) used in particle physics experiments (BaBar, LHC, etc.) for real-time, online radiation monitoring • Development of RadFET based miniaturised wireless dosimetry systems to be implanted in patient body at tumour site for real-time, online, in-vivo dosimetry → Seek funding NPAE-Kyiv2010, Kiev, 7-12/06/10

  22. The imaging challenge • The requirements for new imaging systems: • More accurate, more quantitative and highly repeatable imaging • Imaging during treatment: organ movement (breathing), patient set-up, tumour shrinkage • Image smaller lesions (early diagnosis) • Treatment specific requirements (for ex. Bragg position in proton/light ion therapy) • The answer: higher spatial resolution, higher linearity, lower noise, less drift, faster imaging NPAE-Kyiv2010, Kiev, 7-12/06/10

  23. Time-Of-Flight PET (TOF-PET) • TOF-PET scanner: • Time difference between signals from two crystals measured • Annihilation point along line-of-response directly calculated • Goal: 100 ps timing resolution (ideally 30 ps and below) = 3 cm spatial resolution (ideally sub-cm) • Advantages: higher sensitivity and specificity, improved S/N • Technology needed: fast scintillating materials and fast photon detectors NPAE-Kyiv2010, Kiev, 7-12/06/10

  24. Fast scintillating materials BrilLanCeTM380 and PreLudeTM420 produced by Saint-Gobain Cristaux et Detecteurs NPAE-Kyiv2010, Kiev, 7-12/06/10

  25. 1x1 mm2 3x3 mm2 Hamamatsu Inc. Photon detectors: SiPMs • Array of Silicon Photodiodes on common substrate each operating in Geiger mode • SiPMs have high speed (sub ns) and gain (106) and work in high magnetic fields (7T) NPAE-Kyiv2010, Kiev, 7-12/06/10

  26. Tests on TOF-PET prototypes • LaBr3(Ce) and LYSO scintillating crystals from Saint-Gobain • SiPMs from Hamamatsu, SensL and Photonique • Various two-channel demonstrator systems tested at RAL and RMH • Timing resolution analysis still ongoing NPAE-Kyiv2010, Kiev, 7-12/06/10

  27. Preliminary results • Best SiPMs: Hamamatsu (electrical problem with 11-25) and SensL • Best timing resolutions measured: • 20 ps for single SiPM • 40 ps for pairs of SiPMs • Hamamatsu performance as function of pitch still under investigation • Prototypes with Hamamatsu 3x3mm2 best of all. SensL blind to LaBr3 • Best timing resolutions measured: • 430 ps with 3x3x10 mm3 LYSO • 790 ps with 3x3x30 mm3 LaBr3 • Performance of prototypes with LaBr3 highly dependent from SiPM-crystal coupling NPAE-Kyiv2010, Kiev, 7-12/06/10

  28. Where next with TOF-PET • Preliminary results very encouraging. Next step: dual-head demonstrator system. Two planar heads with identical number of channels → Funded by FP7 as part of ENVISION (European NoVel Imaging Systems for ION therapy) • Use of fast scintillators can be expanded to other imaging systems (CT, SPECT, etc.) • Use of SiPMs opens up the possibility of designing a compact PET/MRI scanner NPAE-Kyiv2010, Kiev, 7-12/06/10

  29. Conclusions • Cancer is a leading cause of mortality in UK. Its incidence is rising. • Radiotherapy is and will be given to a large number of patients. • Patients will benefit from a multi-modality approach to radiotherapy. This requires the development of new, advanced technologies. • Particle physics holds the key to the development of these technologies. NPAE-Kyiv2010, Kiev, 7-12/06/10

  30. Acknowledgements • Dr Phil Evans and Dr Mike Partridge (Royal Marsden Hospital / Institute of Cancer Research - UK) • Prof Ken Peach (John Adams Institute - UK) • Prof Bleddyn Jones (Radiation Oncology and Biology Institute - UK) • The STFC Futures Programme team (UK) • Dr John Matheson and Mr Matt Wilson (STFC-RAL - UK) NPAE-Kyiv2010, Kiev, 7-12/06/10

More Related